Enterprise Value
297.1M
Cash
182M
Avg Qtr Burn
-18.19M
Short % of Float
32.12%
Insider Ownership
0.79%
Institutional Own.
56.89%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Non-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease, metabolic dysfunction-associated steatohepatitis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details metabolic dysfunction-associated steatohepatitis | Phase 2b Data readout | |
Phase 2 Update | ||
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Type 2 diabetes | Phase 1b Update | |
NasoVAX Details Influenza | Failed Discontinued | |
AdCOVID Details COVID-19 | Failed Discontinued | |
HepTCell Details Chronic hepatitis B | Failed Discontinued | |
T-COVID Details COVID-19 | Failed Discontinued | |
NasoShield (Vaccine) Details Anthrax, Bacterial infection | Failed Discontinued |